Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Shares Outstanding (Diluted Average): 2019-2024

Historic Shares Outstanding (Diluted Average) for Ptc Therapeutics (PTCT) over the last 4 years, with Dec 2024 value amounting to $76.8 million.

  • Ptc Therapeutics' Shares Outstanding (Diluted Average) rose 2.68% to $76.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.8 million, marking a year-over-year increase of 2.68%. This contributed to the annual value of $76.8 million for FY2024, which is 2.68% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Shares Outstanding (Diluted Average) of $76.8 million as of Q4 2024, which was down 0.10% from $76.9 million recorded in Q3 2024.
  • In the past 5 years, Ptc Therapeutics' Shares Outstanding (Diluted Average) registered a high of $76.9 million during Q3 2024, and its lowest value of $66.0 million during Q4 2020.
  • Over the past 3 years, Ptc Therapeutics' median Shares Outstanding (Diluted Average) value was $74.8 million (recorded in 2023), while the average stood at $74.3 million.
  • Data for Ptc Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY rose of 12.17% (in 2020) over the last 5 years.
  • Over the past 5 years, Ptc Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $66.0 million in 2020, then climbed by 6.72% to $70.5 million in 2021, then climbed by 1.79% to $71.7 million in 2022, then grew by 4.34% to $74.8 million in 2023, then rose by 2.68% to $76.8 million in 2024.
  • Its Shares Outstanding (Diluted Average) stands at $76.8 million for Q4 2024, versus $76.9 million for Q3 2024 and $76.7 million for Q2 2024.